グリコミクス/糖鎖生物学市場：製品タイプ、用途、エンドユーザー別-2025-2030年の世界予測

グリコミクス/糖鎖生物学市場は、2024年には15億4,000万米ドルとなり、2025年には17億6,000万米ドル、CAGR16.46%で成長し、2030年には38億4,000万米ドルに達すると予測されています。

グライコミクスと糖鎖生物学は、生物医学研究とイノベーションの中で極めて重要な分野として浮上しており、様々な生物学的プロセスにおける糖鎖の構造と機能に関する深い洞察を提供しています。最先端の技術と手法の統合により、疾病診断と治療開発の新時代が到来し、科学者と意思決定者の健康と疾病に対する捉え方が根本的に変化しています。

タンパク質グリコシル化研究と糖鎖プロファイリングにおける最近の進歩は、新規バイオマーカー発見、患者層別化の改善、細胞シグナル伝達経路のより深い理解への道を開いた。これらの分野が急速な進化を続ける中、化学、生物学、テクノロジーを融合させた学際的アプローチが、臨床現場や医薬イノベーションに影響を与える画期的なブレークスルーの舞台を整えつつあります。

グリコミクス/糖鎖生物学市場の変革

この10年間で、糖鎖科学と糖鎖生物学は大きく変化しました。科学的なブレークスルーと技術の進歩が相まって、研究パラメーターと市場力学が再定義されました。研究者は現在、複雑な糖鎖構造とその生物学的役割を解明するために、次世代シーケンサー、ハイスループットスクリーニング、高度なモデリングプラットフォームを活用しています。

革新的な診断技術は、がんや遺伝性疾患の検出を加速しただけでなく、感染症診断の視野を広げ、より個別化されたヘルスケアソリューションにつながっています。これと並行して、糖鎖をベースとした治療薬やドラッグデリバリーシステムの急速な開発は、製薬・バイオテクノロジー部門に活路を開き、研究開発への旺盛な投資を促しています。

さらに、人工知能と機械学習アルゴリズムが糖鎖分析に統合されたことで、データ処理が合理化され、予測結果が向上し、精密医療へのシフトが業界全体に広がっています。このような情勢は、研究および臨床応用の両方におけるパラダイムシフトを裏付けるような、俊敏で技術主導型のアプローチに従来の手法が急速に取って代わられつつあるダイナミックな性質を反映しています。

イノベーションを推進する包括的なセグメンテーションの洞察

グリコミクス市場のセグメンテーションインサイトは、業界動向と有望な成長機会を理解する上で重要な、複雑な分析層を明らかにしています。製品タイプ別に市場を評価する場合、酵素、機器、キット、試薬・化学品を対象とします。酵素分析では、グリコシダーゼとノイラミダーゼの組み合わせ、グリコシルトランスフェラーゼとシアリルトランスフェラーゼの組み合わせ、タンパク質硫酸転移酵素とスルファターゼの組み合わせなどのカテゴリーを掘り下げています。このようなきめ細かなアプローチにより、各酵素サブグループに合わせた戦略の策定が容易になります。

機器は極めて重要な役割を果たしており、アレイ、クロマトグラフィー機器、電気泳動機器、HPLCカラム、質量分析機器にまで及ぶ詳細な評価が行われています。これらのツールは方法論の進歩の最前線にあり、高精度の糖鎖プロファイリングを可能にし、複雑なバイオテクノロジー応用を促進します。同様に、キットのカテゴリーでは、グリカン検出キット、グリカン濃縮キット、グリカン標識キット、グリカンプロファイリングキット、グリカン精製キット、グリカン放出キット、グリカンサンプル調製キット、グリカンシークエンシングキットなど、さまざまな技術ツールに関する洞察を提供します。これらのソリューションはそれぞれ、糖鎖分析の感度と特異性を高めるように設計されているため、診断と治療研究に対する重層的なアプローチをサポートします。

さらに、市場は診断と治療に重点を置いたアプリケーションに基づいて分析されています。診断の面では、早期発見と戦略的介入の重要性を強調し、がん検出、遺伝性疾患、感染症などのアプリケーションを分析しています。治療への応用も同様に堅固で、ドラッグデリバリーシステム、医薬品開発、創薬の項目でさらに評価されており、それぞれが臨床上の様々な課題に対処する上で重要な役割を果たしています。

エンドユーザーのセグメンテーションは、学術研究機関、受託研究機関、製薬・バイオテクノロジー企業などの明確な事業体を考慮することで、市場展望をさらに細分化します。この包括的なセグメンテーション評価により、個々の市場促進要因、投資パターン、将来の成長軌道の微妙な理解が容易になり、利害関係者が研究の優先順位を効果的に絞り込み、戦略的にリソースを配分できるようになります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療のニーズの高まりがグリコミクスに基づく診断ツールの開発を加速
    • グリカンベースの治療法を必要とする慢性疾患の罹患率の増加
  • 抑制要因
    • グリコミクス調査に関連するデータの統合と標準化の欠如
  • 機会
    • 質量分析法の継続的な進歩により、グリコミクスプロファイリングと機能が向上しています。
    • グリコミクスの研究開発イニシアチブに対する政府の資金提供とパートナーシップを世界的に増加
  • 課題
    • 高品質のグリカンライブラリと試薬の入手が限られている
• 市場セグメンテーション分析
  • 製品タイプ：利便性とユーザーフレンドリーな性質によりキットの需要が高まっています
  • アプリケーション：診断におけるグリコミクス/糖鎖生物学の重要な役割
  • エンドユーザー：製薬会社およびバイオテクノロジー企業におけるグリコミクス/糖鎖生物学の幅広い応用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 グリコミクス/糖鎖生物学市場：製品タイプ別

• 酵素
  • グリコシダーゼとノイラミダーゼ
  • グリコシルトランスフェラーゼとシアリルトランスフェラーゼ
  • タンパク質スルホトランスフェラーゼとスルファターゼ
• 機器
  • 配列
  • クロマトグラフィー機器
  • 電気泳動装置
  • HPLCカラム
  • 質量分析装置
• キット
  • グリカン検出キット
  • グリカン濃縮キット
  • グリカン標識キット
  • グリカンプロファイリングキット
  • グリカン精製キット
  • グリカン放出キット
  • グリカンサンプル調製キット
  • グリカンシーケンシングキット
• 試薬・化学薬品

第7章 グリコミクス/糖鎖生物学市場：用途別

• 診断
  • がん検出
  • 遺伝性疾患
  • 感染症
• 治療薬
  • ドラッグデリバリーシステム
  • 医薬品開発
  • 創薬

第8章 グリコミクス/糖鎖生物学市場：エンドユーザー別

• 学術調査機関
• 契約調査機関
• 製薬・バイオテクノロジー企業

第9章 南北アメリカのグリコミクス/糖鎖生物学市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のグリコミクス/糖鎖生物学市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのグリコミクス/糖鎖生物学市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies, Inc.
• AMSBIO
• Asparia Glycomics
• Bio-Techne Corporation
• Bruker Corporation
• Chemily Glycoscience
• Creative Diagnostics
• FUJIFILM Wako Pure Chemical Corporation
• Genos Glyco
• Glycan Therapeutics
• GlycoDiag
• glyXera GmbH
• ICE S.p.a.
• Lectenz Bio, Inc.
• Ludger Ltd
• Megazyme Ltd. by Neogen Corporation
• Merck KGaA
• New England Biolabs, Inc.
• QIAGEN N.V.
• RayBiotech, Inc.
• Revvity, Inc.
• SCIEX by Danaher Corporation
• Shimadzu Corporation
• Sumitomo Bakelite Co., Ltd.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Tokyo Chemical Industry Co., Ltd.
• Vector Laboratories, Inc.
• Waters Corporation
• Z Biotech, LLC
• Zacharon Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. GLYCOMICS/GLYCOBIOLOGY MARKET MULTI-CURRENCY
• FIGURE 2. GLYCOMICS/GLYCOBIOLOGY MARKET MULTI-LANGUAGE
• FIGURE 3. GLYCOMICS/GLYCOBIOLOGY MARKET RESEARCH PROCESS
• FIGURE 4. GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2018-2030 (USD THOUSAND)
• FIGURE 6. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 7. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 8. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 10. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 12. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 14. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 15. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 16. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 17. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 18. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
• FIGURE 22. GLYCOMICS/GLYCOBIOLOGY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 23. GLYCOMICS/GLYCOBIOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. GLYCOMICS/GLYCOBIOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2018-2030 (USD THOUSAND)
• TABLE 4. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 5. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 6. GLYCOMICS/GLYCOBIOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 8. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 9. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOSIDASES & NEURAMIDASES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 10. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOSYLTRANSFERASES & SIALYTRANSFERASES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 11. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PROTEIN SULFOTRANSFERASES & SULFATASES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 12. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 13. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 14. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ARRAYS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 15. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 16. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ELECTROPHORESIS INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 17. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY HPLC COLUMNS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 18. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY MASS SPECTROMETRY INSTRUMENTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 19. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 20. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 21. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN DETECTION KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 22. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN ENRICHMENT KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 23. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN LABELING KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 24. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN PROFILING KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 25. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN PURIFICATION KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 26. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN RELEASING KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 27. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN SAMPLE PREPARATION KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 28. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN SEQUENCING KITS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 29. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 30. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REAGENTS & CHEMICALS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 31. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 32. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 33. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 34. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 35. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 36. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 37. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 38. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 39. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 40. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 41. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 42. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 43. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 44. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 45. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 46. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 47. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 48. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 49. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 50. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 51. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 52. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 53. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 54. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 55. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 56. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 57. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 58. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 59. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 60. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 61. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 62. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 63. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 64. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 65. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 66. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 67. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 68. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 69. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 70. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 71. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 72. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 73. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 74. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 75. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 76. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 77. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 78. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 79. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 80. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 81. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 82. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 83. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 84. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 85. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 86. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 87. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 88. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 89. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 90. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 91. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 92. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 93. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 94. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 95. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
• TABLE 96. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 97. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 98. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 99. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 100. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 101. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 102. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 103. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 104. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 105. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 106. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 107. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 108. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 109. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 110. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 111. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 112. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 113. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 114. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 115. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 116. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 117. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 118. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 119. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 120. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 121. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 122. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 123. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 124. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 125. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 126. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 127. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 128. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 129. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 130. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 131. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 132. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 133. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 134. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 135. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 136. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 137. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 138. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 139. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 140. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 141. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 142. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 143. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 144. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 145. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 146. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 147. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 148. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 149. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 150. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 151. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 152. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 153. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 154. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 155. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 156. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 157. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 158. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 159. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 160. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 161. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 162. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 163. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 164. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 165. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 166. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 167. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 168. SINGAPORE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 169. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 170. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 171. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 172. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 173. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 174. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 175. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 176. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 177. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 178. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 179. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 180. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 181. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 182. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 183. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 184. TAIWAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 185. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 186. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 187. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 188. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 189. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 190. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 191. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 192. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 193. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 194. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 195. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 196. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 197. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 198. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 199. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 200. VIETNAM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 210. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 211. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 212. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 213. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 214. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 215. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 216. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 217. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 218. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 219. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 220. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 221. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 222. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 223. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 224. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 225. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 226. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 227. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 228. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 229. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 230. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 231. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 232. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 233. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 234. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 235. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 236. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 237. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 238. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 239. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 240. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 241. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 242. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 243. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 244. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 245. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 246. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 247. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 248. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 249. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 250. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 251. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 252. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 253. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 254. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 255. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 256. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 257. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 258. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 259. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 260. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 261. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 262. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 263. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 264. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 265. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 266. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 267. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 268. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 269. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 270. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 271. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 272. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 273. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 274. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 275. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 276. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 277. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 278. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 279. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 280. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 281. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 282. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 283. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 284. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 285. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 286. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 287. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 288. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 289. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 290. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 291. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 292. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 293. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 294. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 295. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 296. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 297. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 298. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 299. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 300. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 301. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 302. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 303. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 304. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 305. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 306. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 307. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 308. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 309. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 310. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 311. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 312. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 313. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 314. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 315. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 316. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 317. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 318. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 319. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 320. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 321. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 322. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 323. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 324. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 325. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 326. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 327. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 328. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 329. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 330. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 331. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD THOUSAND)
• TABLE 332. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD THOUSAND)
• TABLE 333. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD THOUSAND)
• TABLE 334. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD THOUSAND)
• TABLE 335. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD THOUSAND)
• TABLE 336. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD THOUSAND)
• TABLE 337. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 338. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD THOUSAND)
• TABLE 339.

The Glycomics/Glycobiology Market was valued at USD 1.54 billion in 2024 and is projected to grow to USD 1.76 billion in 2025, with a CAGR of 16.46%, reaching USD 3.84 billion by 2030.

Glycomics and glycobiology have emerged as pivotal fields within biomedical research and innovation, offering profound insights into the structure and function of carbohydrates in various biological processes. The integration of cutting-edge technologies and methodologies has ushered in a new era of disease diagnostics and therapeutic development, fundamentally altering how scientists and decision-makers perceive health and disease.

Recent advancements in protein glycosylation studies and carbohydrate profiling have paved the way for novel biomarker discoveries, improved patient stratification, and a deeper understanding of cellular signaling pathways. As these fields continue evolving rapidly, the interdisciplinary approach uniting chemistry, biology, and technology is setting the stage for transformative breakthroughs that impact clinical practice and pharmaceutical innovation.

Transformative Shifts in the Glycomics and Glycobiology Landscape

The last decade has witnessed transformative shifts in glycomics and glycobiology. Scientific breakthroughs, coupled with technological advancements, have redefined research parameters and market dynamics. Researchers now leverage next-generation sequencing, high-throughput screening, and sophisticated modeling platforms to demystify complex carbohydrate structures and their biological roles.

Innovative diagnostic techniques have not only accelerated the detection of cancer and genetic disorders but have also expanded the horizons for infectious disease diagnosis, leading to more personalized healthcare solutions. In parallel, the rapid development of glycan-based therapeutics and drug delivery systems has opened avenues for the pharmaceutical and biotechnology sectors, stimulating robust investments in research and development.

Furthermore, the integration of artificial intelligence and machine learning algorithms into glycan analytics has streamlined data processing and enhanced predictive outcomes, underscoring an industry-wide shift toward precision medicine. These milestones reflect the dynamic nature of the landscape, where traditional practices are rapidly being replaced by agile, technology-driven approaches that underline a paradigm shift in both research and clinical applications.

Comprehensive Segmentation Insights Driving Innovation

The segmentation insights in the glycomics market reveal intricate layers of analysis that are critical in understanding industry trends and promising growth opportunities. When evaluating the market based on product type, the study encompasses enzymes, instruments, kits, and reagents & chemicals. Enzyme analysis delves into categories such as glycosidases paired with neuramidases, glycosyltransferases together with sialytransferases, as well as protein sulfotransferases combined with sulfatases. This granular approach facilitates tailored strategy formulations for each enzymatic subgroup.

Instruments play a pivotal role, with detailed assessments extending to arrays, chromatography instruments, electrophoresis instruments, HPLC columns, and mass spectrometry instruments. These tools are at the forefront of methodological advancements, enabling highly accurate glycan profiling and facilitating complex biotechnological applications. Similarly, the kits category offers insights into a range of technical tools, including glycan detection kits, glycan enrichment kits, glycan labeling kits, glycan profiling kits, glycan purification kits, glycan releasing kits, glycan sample preparation kits, and glycan sequencing kits. Each of these solutions is designed to enhance sensitivity and specificity in glycan analysis, thus supporting a layered approach to diagnostics and therapeutic research.

Furthermore, the market is analyzed based on applications where the focus is placed on diagnostics and therapeutics. On the diagnostics front, the analysis covers applications in cancer detection, genetic disorders, and infectious diseases, highlighting the importance of early detection and strategic intervention. Therapeutic applications are equally robust, being further evaluated under drug delivery systems, drug development, and drug discovery, each playing a key role in addressing various clinical challenges.

The end-user segmentation further refines the market outlook by considering distinct entities such as academic research institutes, contract research organizations, and pharmaceutical & biotechnology companies. This comprehensive segmentation assessment facilitates a nuanced understanding of individual market drivers, investment patterns, and future growth trajectories, enabling stakeholders to effectively target their research priorities and allocate resources strategically.

Based on Product Type, market is studied across Enzymes, Instruments, Kits, and Reagents & Chemicals. The Enzymes is further studied across Glycosidases & Neuramidases, Glycosyltransferases & Sialytransferases, and Protein Sulfotransferases & Sulfatases. The Instruments is further studied across Arrays, Chromatography Instruments, Electrophoresis Instruments, HPLC Columns, and Mass Spectrometry Instruments. The Kits is further studied across Glycan Detection Kits, Glycan Enrichment Kits, Glycan Labeling Kits, Glycan Profiling Kits, Glycan Purification Kits, Glycan Releasing Kits, Glycan Sample Preparation Kits, and Glycan Sequencing Kits.

Based on Applications, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Cancer Detection, Genetic Disorders, and Infectious Diseases. The Therapeutics is further studied across Drug Delivery Systems, Drug Development, and Drug Discovery.

Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.

Regional Dynamics Shaping the Global Glycomics Market

Regional insights indicate that market evolution is influenced by variations in research funding, technological adoption, and regulatory landscapes. In the Americas, well-established research infrastructures and high investments in biopharmaceutical research encourage significant progress, fostering a dynamic research environment autochthonous to groundbreaking diagnostic and therapeutic projects.

The region comprising Europe, the Middle East, and Africa exemplifies a balanced mix of robust academic research and industrial initiatives. Europe stands out with its advanced technological platforms and strategic alliances, while the Middle East and Africa showcase emerging markets keen on leveraging glycomics as a driver for future healthcare innovations.

Across the Asia-Pacific region, rapid technological advancements and expanding research capabilities contribute robustly to the overall market growth. Countries in this region are increasingly investing in research and clinical applications, thereby accelerating the adoption of novel glycomics technologies and solutions. These regional dynamics underscore the fact that global market trends are not homogenous but instead reflect a blend of local priorities, economic conditions, and infrastructural strengths, driving a complex yet promising global market landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Innovators and Industry Pioneers

Key company insights reveal that the competitive landscape is enriched by an array of leading innovators and technology pioneers who continue to redefine standards in glycomics and glycobiology. Firms such as Agilent Technologies, Inc. and AMSBIO are setting benchmarks with advanced instrumentation and high-quality reagents that enable precise and efficient glycan analysis. Emerging players like Asparia Glycomics and Bio-Techne Corporation have contributed innovative solutions that cater to specific needs in both research and clinical settings.

Other influential companies such as Bruker Corporation and Chemily Glycoscience have made significant strides in the development of state-of-the-art analytical instruments and diagnostic kits, forging new paths in glycomics technology. Creative Diagnostics, FUJIFILM Wako Pure Chemical Corporation, and Genos Glyco have played substantial roles in product diversification and technological refinement, thereby expanding the application horizons. Additionally, Glycan Therapeutics, GlycoDiag, and glyXera GmbH are notable for their contributions to therapeutic advancements, while ICE S.p.a., Lectenz Bio, Inc., and Ludger Ltd. are recognized for pioneering dedicated enzymatic and assay solutions.

The competitive ecosystem is further enriched by companies such as Megazyme Ltd. by Neogen Corporation, Merck KGaA, and New England Biolabs, Inc., which maintain high standards in research and product development. Key market players like QIAGEN N.V., RayBiotech, Inc., and Revvity, Inc. continue to bolster growth by providing integrated platforms that combine automation and precision. Industry leaders such as SCIEX by Danaher Corporation, Shimadzu Corporation, and Sumitomo Bakelite Co., Ltd. are relentlessly pushing the frontiers of technology. Lastly, Takara Bio Inc., Thermo Fisher Scientific Inc., Tokyo Chemical Industry Co., Ltd., Vector Laboratories, Inc., Waters Corporation, Z Biotech, LLC, and Zacharon Pharmaceuticals, Inc. complete this constellation of enterprises, collectively driving industry innovation and spearheading the evolution of market strategies.

The report delves into recent significant developments in the Glycomics/Glycobiology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., AMSBIO, Asparia Glycomics, Bio-Techne Corporation, Bruker Corporation, Chemily Glycoscience, Creative Diagnostics, FUJIFILM Wako Pure Chemical Corporation, Genos Glyco, Glycan Therapeutics, GlycoDiag, glyXera GmbH, ICE S.p.a., Lectenz Bio, Inc., Ludger Ltd, Megazyme Ltd. by Neogen Corporation, Merck KGaA, New England Biolabs, Inc., QIAGEN N.V., RayBiotech, Inc., Revvity, Inc., SCIEX by Danaher Corporation, Shimadzu Corporation, Sumitomo Bakelite Co., Ltd., Takara Bio Inc., Thermo Fisher Scientific Inc., Tokyo Chemical Industry Co., Ltd., Vector Laboratories, Inc., Waters Corporation, Z Biotech, LLC, and Zacharon Pharmaceuticals, Inc.. Strategic Recommendations for Market Leadership

For industry leaders navigating the challenges of an evolving glycomics and glycobiology market, formulating strategic recommendations is essential. It is imperative to invest in advanced technologies and robust analytics that can capture and process the complex data derived from glycan structures. Using integrated, high-throughput platforms will not only enhance analytical precision but will also aid in reducing turnaround times for critical diagnostics and research initiatives.

Leaders should prioritize the development of strong collaborative networks with academic and research institutions, ensuring that cross-disciplinary efforts translate into breakthrough solutions in diagnostics and therapeutics. Furthermore, aligning with regulatory bodies to streamline approval processes and ensure adherence to quality standards is crucial for accelerating market entry and sustaining competitive advantage. Investment in workforce talent and continuous training further supports the adoption of next-generation technologies, enabling teams to harness cutting-edge methodologies effectively.

Another key approach involves fostering strategic partnerships with technology innovators and established market players. These collaborations can create synergies that drive advancements in product development and open new market avenues. Companies are advised to diversify their portfolios across various segments such as enzymes, instruments, and kits, ensuring that there is a robust foundation to support both diagnostic and therapeutic applications.

Simultaneously, leveraging regional strengths and tailoring strategies to local market dynamics will strengthen global outreach. Executives should carry out comprehensive market analyses that consider the distinctive research environments and regulatory landscapes across regions including the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Streamlined integration of research insights with market strategies will fortify the positioning of any enterprise poised to lead in this competitive domain.

Summarizing the Strategic Landscape of Glycomics

In summary, the dynamic landscape of glycomics and glycobiology presents an array of opportunities that mirror the complexity and potential of carbohydrate research. The transformative shifts, underpinned by technological advancements and rising market segmentation, showcase an industry in transition. Detailed insights into product types, application areas, and end-user dynamics highlight the multifaceted nature of this sector, reinforcing its relevance in both the academic and clinical realms.

Key takeaways emphasize the role of innovative diagnostics and therapeutic strategies, the importance of precision instrumentation, and the significant impact of market-specific segmentation. Furthermore, the regional variations and competitive landscape underscore a globally interconnected market that is ripe for innovation. As industry trends continue to morph and expand, the synthesis of technological advancements with strategic market positioning remains critical for differentiating and accelerating growth.

This comprehensive understanding not only provides a roadmap for navigating future challenges but also sets the stage for pioneering approaches that resonate with the evolving needs of patients, researchers, and industry stakeholders alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising need for personalized medicine amplifying glycomics-based diagnostic tools development
    • 5.1.1.2. Increasing prevalence of chronic diseases necessitating glycan-based therapeutic approaches
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of data integration and standardization associated with glycomics research
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in mass spectrometry enhancing glycomic profiling and capabilities
    • 5.1.3.2. Increasing government funding and partnerships for glycomics research and development initiatives globally
  • 5.1.4. Challenges
    • 5.1.4.1. Limited availability of high-quality glycan libraries and reagents
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Increasing need for kits due to their convenience and user-friendly nature
  • 5.2.2. Applications: Crucial role of glycomics/glycobiology in diagnostics
  • 5.2.3. End-User: Widespread application of glycomics/glycobiology in pharmaceutical & biotechnology companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glycomics/Glycobiology Market, by Product Type

• 6.1. Introduction
• 6.2. Enzymes
  • 6.2.1. Glycosidases & Neuramidases
  • 6.2.2. Glycosyltransferases & Sialytransferases
  • 6.2.3. Protein Sulfotransferases & Sulfatases
• 6.3. Instruments
  • 6.3.1. Arrays
  • 6.3.2. Chromatography Instruments
  • 6.3.3. Electrophoresis Instruments
  • 6.3.4. HPLC Columns
  • 6.3.5. Mass Spectrometry Instruments
• 6.4. Kits
  • 6.4.1. Glycan Detection Kits
  • 6.4.2. Glycan Enrichment Kits
  • 6.4.3. Glycan Labeling Kits
  • 6.4.4. Glycan Profiling Kits
  • 6.4.5. Glycan Purification Kits
  • 6.4.6. Glycan Releasing Kits
  • 6.4.7. Glycan Sample Preparation Kits
  • 6.4.8. Glycan Sequencing Kits
• 6.5. Reagents & Chemicals

7. Glycomics/Glycobiology Market, by Applications

• 7.1. Introduction
• 7.2. Diagnostics
  • 7.2.1. Cancer Detection
  • 7.2.2. Genetic Disorders
  • 7.2.3. Infectious Diseases
• 7.3. Therapeutics
  • 7.3.1. Drug Delivery Systems
  • 7.3.2. Drug Development
  • 7.3.3. Drug Discovery

8. Glycomics/Glycobiology Market, by End-User

• 8.1. Introduction
• 8.2. Academic Research Institutes
• 8.3. Contract Research Organizations
• 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Glycomics/Glycobiology Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Glycomics/Glycobiology Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Glycomics/Glycobiology Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. FPNV Positioning Matrix, 2024
• 12.3. Competitive Scenario Analysis
  • 12.3.1. OBI Pharma collaboration with GlyTech to expand GlycOBI enabling technologies and to advance glycan production in Japan
  • 12.3.2. Michael Smith Health Research BC partners with GlycoNet with investment of USD 2.3 million
  • 12.3.3. GlycoNet invests USD 12 million in Canadian glycomics research to tackle health and agriculture challenges
  • 12.3.4. UK Biotechnology and Biological Sciences Research Council(BBSRC) awarded GBP 1.1 million in funds to Queen Mary University of London and Imperial College London
  • 12.3.5. GlycoNet and CQDM's transformative partnership aims to enhance drug discovery and healthcare solutions in Canada
  • 12.3.6. UGA receives an NSF award worth USD 18 million to broaden access to glycoscience
  • 12.3.7. GlycoNet and NOVA FCT collaborate to drive innovations in glycomics and glycoscience
  • 12.3.8. ReNAgade Therapeutics strengthens merger with GanNA Bio paving new pathways in glycomics research
  • 12.3.9. DAZZEON JAPAN strategic partnership with Hoshi University to innovate gastric lesion treatments through research
  • 12.3.10. Vector Laboratories partners with Navinci Diagnostics to innovate spatial proteomics for advanced biomarker discovery in glycosylation detection
• 12.4. Strategy Analysis & Recommendation
  • 12.4.1. Revvity, Inc.
  • 12.4.2. Ludger Ltd
  • 12.4.3. Vector Laboratories, Inc.
  • 12.4.4. Thermo Fisher Scientific Inc.

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. AMSBIO
• 3. Asparia Glycomics
• 4. Bio-Techne Corporation
• 5. Bruker Corporation
• 6. Chemily Glycoscience
• 7. Creative Diagnostics
• 8. FUJIFILM Wako Pure Chemical Corporation
• 9. Genos Glyco
• 10. Glycan Therapeutics
• 11. GlycoDiag
• 12. glyXera GmbH
• 13. ICE S.p.a.
• 14. Lectenz Bio, Inc.
• 15. Ludger Ltd
• 16. Megazyme Ltd. by Neogen Corporation
• 17. Merck KGaA
• 18. New England Biolabs, Inc.
• 19. QIAGEN N.V.
• 20. RayBiotech, Inc.
• 21. Revvity, Inc.
• 22. SCIEX by Danaher Corporation
• 23. Shimadzu Corporation
• 24. Sumitomo Bakelite Co., Ltd.
• 25. Takara Bio Inc.
• 26. Thermo Fisher Scientific Inc.
• 27. Tokyo Chemical Industry Co., Ltd.
• 28. Vector Laboratories, Inc.
• 29. Waters Corporation
• 30. Z Biotech, LLC
• 31. Zacharon Pharmaceuticals, Inc.